Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Summary
The study is being conducted to evaluate the efficacy, safety, and ORR of HRS-4508 combination with other anti tumor therapy in subjects with solid tumor ; to evaluate HRS4508 DLT, MTD and RP2D, to evaluate the incidence and severity of adverse events (AE)/serious adverse events (SAE) (rated based on CTCAE v5.0), to evaluate ORR by researchers based on RECIST v1.1, to evaluate the pharmacokinetic (PK) characteristics of HRS-4508 SHR-1811, Capecitabine.
Official title: An Open, Multicenter Phase IB/II Clinical Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2025-10
Completion Date
2028-10
Last Updated
2025-08-24
Healthy Volunteers
No
Conditions
Interventions
HRS-4508+ Capecitabine
HRS-4508+ Capecitabine
HRS-4508+ Trastuzumab
HRS-4508+ Trastuzumab
HRS-4508+ Trastuzumab+ Pertuzumab
HRS-4508+ Trastuzumab+ Pertuzumab
HRS-4508+ Trastuzumab+ Capecitabine
HRS-4508+ Trastuzumab+ Capecitabine
Trastuzumab+ Capecitabine
Trastuzumab+ Capecitabine
HRS-4508+A1811
HRS-4508+A1811
Locations (1)
Cancer Hospital Chinese Academy of Medical Science
Beijing, Beijing Municipality, China